The procedures described were approved by the IV Local Ethics Committee for the Care and Use of Laboratory Animals for Experimental Procedures, National Medicines Institute in Warsaw.
Male, adult Wistar rats (270-310g, n = 38) were provided by the Animal House of Mossakowski Medical Research Institute, PAS. The animals were anesthetized with 5% halothane in N2O/O2 (70%/30%) and decapitated. The brain was removed and immersed in cold (4°C) 3-(N-morpholino)propanesulfonic acid (MOPS)– buffered saline solution with 1% dialyzed bovine serum albumin (BSA) at pH 7.40.
Isolation and mounting of the MCA
Middle cerebral arteries (n = 76) were isolated and mounted in the organ chamber according to the procedure as described [22]. Briefly, MCA was dissected and cleaned of connective tissue. A 3 mm long segment was transferred to the organ chamber filled with MOPS-buffered saline solution containing 1% dialyzed BSA, mounted between two glass micropipettes, and fixed. An inlet pipette was connected to a pressure-servo system. The MCA was perfused at a rate 100 µl/min with MOPS–buffered saline solution containing 1% dialyzed BSA at an intraluminal pressure of 80 mm Hg. The extraluminal bath was replaced with a MOPS buffered saline solution without BSA, slowly heated to 37°C and exchanged at a rate of 20 ml/min with the help of a peristaltic pump (Masterflex, Cole Parmer, USA). The chamber was placed on the stage of an inverted light microscope (Olympus CKX41) equipped with a video camera and a monitor. The internal diameter of the vessel was measured directly from the screen and recorded for off-line analysis. During the equilibration period (1 hour) the vessel slowly developed a myogenic tone (constriction by approximately 35% of the initial diameter). After this time, the response to increased potassium ion concentration (20 mmol L-1) in the extraluminal bath was tested. Vessels which did not develop a myogenic tone or responded with less than a 25% increase in the diameter to 20 mmol L-1 KCl were discarded.
Experimental protocol
After the KCl reactivity test and 15 minutes equilibration period in the MOPS-buffered saline, the vessel was studied according to one of the following paradigms (Table 1). Series 0 was a time control study in which pressurized and KCl reactivity tested MCA was maintained in a MOPS buffered physiological saline solution (Na+ = 145 mmol L-1) and continuously monitored for 180 minutes to find out whether the diameter is stable over time which is needed to perform the longest of the experiments listed below. In series I, the intra- and extraluminal concentration of Na+ was decreased to 121 mmol L-1 for 180 minutes. Although 60th minute was chosen as a reference time for the measurement of MCA diameter, the vessel was left in low sodium buffer up to 180 minutes to test the stability of MCA diameter under this condition. This low sodium buffer had an osmolality of 268 ± 5 mOsm kg-1. In series II, the intra- and extraluminal concentration of Na+ was lowered similarly as in series I but the osmolality of the buffer was maintained at 300 ± 3 mOsm kg-1 with N-methyl-D-glucamine (NMDG). In the remaining series of experiments, the MOPS buffered saline solution contained 121 mmol L-1 Na+ and was hypoosmotic (268 ± 5 mOsm kg-1). In series III, the participation of endothelial cells in the response of MCA to lowering of Na+ concentration to 121 mmol L-1 was investigated. Endothelial cells were removed before decreasing Na+ concentration by blowing 8 ml of air through the lumen of the vessel for 15 minutes. The effectiveness of endothelium removal was confirmed by the absence of dilation in response to the intraluminal administration of acetylcholine (ACh, 100 µmol L-1). Next, the response to the lowering of Na+ concentration was studied similarly as in series I. In series IV and V, the participation of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the response of the MCA to 121 mmol L-1 Na+ was tested. To inhibit NO production, 30 minutes before the lowering of Na+ concentration, a nonselective NO synthase (NOS) inhibitor - NG-nitro-L-arginine methyl ester (L-NAME, 10 µmol L-1) was added to the extravascular perfusate. The synthesis of cGMP was inhibited by the administration of the compound 1H-[1,2,4]Oxadiozolo[4,3-a]quinoxalin-1-one (ODQ, 5 µmol L-1) to the extravascular perfusate 30 minutes before lowering of Na+ concentration. Series VI was designed to study participation of the reverse mode of Na+/Ca2+ exchanger in the response of the MCA to low sodium environment. In this series, (2-[2-[4-(4-nitrobenzyloxy)phenyl] ethyl isothiourea mesylate (KB-R7943, 10 µmol L-1) was administered to the normal sodium MOPS-buffered saline solution prior to the lowering of sodium ions concentration and maintained throughout the observation time. This dose of KB-R7943 has been used to inhibit Ca2+-entry mode of Na+/Ca2+ exchanger in the endothelial cells.32,33
In series VII, nimodipine (100 nmol L-1) – the antagonist of L-type Ca2+ membrane channels of vascular smooth muscle, was administered to the buffer prior to the lowering of sodium concentration. This experiment was designed to test whether relaxation of the wall of the MCA prior to the application of low sodium buffer affects vasodilatory capacity of the vessel. In the experiment with nimodipine care was taken to avoid light inactivation of the drug.
Table 1 List of the experimental series
series
|
paradigm
|
MCA diameter
|
0
|
145 mmol L-1 Na+ for 180 minutes
|
no change
|
I
|
121 mmol L-1 Na+ for 180 minutes
|
stable dilation
|
II
|
121 mmol L-1 Na+ + NMDG
|
dilation
|
III
|
- Endo + 121 mmol L-1 Na+
|
no change
|
IV
|
L-Name + 121 mmol L-1 Na+
|
constriction
|
V
|
ODQ + 121 mmol L-1 Na+
|
constriction
|
VI
|
121 mmol L-1 Na+ + KB-R7943
|
no change
|
VII
|
121 mmol L-1 Na+ + Nimodipine
|
dilation
|
Drugs and solutions
The normonatremic MOPS buffered saline solution contained (in mmol L-1): 144.0 NaCl, 3.0 KCl, 2.5 CaCl2, 1.5 MgSO4, 1.21 NaH2PO4, 0.02 EDTA, 2.0 pyruvate, 5.0 glucose, 2.0 MOPS. The concentration of solutes in the hyponatremic MOPS buffer was the same as in the normonatremic one except for NaCl which was lowered to 120 mmol L-1 to obtain Na+ concentration in the buffer equal to 121 mmol L-1. The hyponatremic MOPS buffer was hypoosmotic in all but one series (series II) of the experiments in which the osmotic pressure was maintained at 300 ± 3 mOsm kg-1 as mentioned above. Acetylcholine chloride, NMDG, L-NAME and nimodipine were purchased from Sigma-Aldrich. ODQ and KB-R7943 mesylate were obtained from Tocris Cookson Ltd. The drugs were dissolved in a MOPS buffered saline solution except for ODQ and KB-R7943 mesylate which were prepared in DMSO and added to the buffer. The final concentration of DMSO in the MOPS buffered saline did not exceed 0,005%. According to the results of a pilot study, this concentration of DMSO does not affect the diameter of MCA.
Data analysis
All data is presented as mean ± standard error (S.E.), n denotes the total number of rats used or the number of vessels per group. The differences between the groups were assessed using one way analysis of variance (ANOVA) followed by post hoc Tukey’s comparison (Statistica 10). Single comparisons were made using the Student’s t-test for paired or unpaired data when appropriate. The differences were considered statistically significant at p<0.05.